[go: up one dir, main page]

WO2013058527A3 - Combined formulation of leukotriene antagonist and epinastine - Google Patents

Combined formulation of leukotriene antagonist and epinastine Download PDF

Info

Publication number
WO2013058527A3
WO2013058527A3 PCT/KR2012/008458 KR2012008458W WO2013058527A3 WO 2013058527 A3 WO2013058527 A3 WO 2013058527A3 KR 2012008458 W KR2012008458 W KR 2012008458W WO 2013058527 A3 WO2013058527 A3 WO 2013058527A3
Authority
WO
WIPO (PCT)
Prior art keywords
epinastine
leukotriene antagonist
combined formulation
active ingredients
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/008458
Other languages
French (fr)
Korean (ko)
Other versions
WO2013058527A2 (en
Inventor
이창규
박상근
최현주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navipharm Co Ltd
Original Assignee
Navipharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120069220A external-priority patent/KR101278572B1/en
Application filed by Navipharm Co Ltd filed Critical Navipharm Co Ltd
Priority to CN201280051128.XA priority Critical patent/CN103889424A/en
Publication of WO2013058527A2 publication Critical patent/WO2013058527A2/en
Publication of WO2013058527A3 publication Critical patent/WO2013058527A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a combined formulation of a leukotriene antagonist and epinastine containing a leukotriene antagonist and epinastine as active ingredients, comprising a pharmaceutical unit, wherein any one of the two active ingredients have an environment separated from that of the other, and a preparation method thereof. The combined formulation has an excellent dissolution rate and bioavailability of a leukotriene antagonist. Furthermore, the two active ingredients synergically reduce eosinophils or inhibit airway hyperresponsiveness, and thus the combined formulation can be very useful for preventing or treating bronchial asthma.
PCT/KR2012/008458 2011-10-18 2012-10-17 Combined formulation of leukotriene antagonist and epinastine Ceased WO2013058527A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280051128.XA CN103889424A (en) 2011-10-18 2012-10-17 Compound preparation of leukotriene antagonist and epinastine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110106382 2011-10-18
KR10-2011-0106382 2011-10-18
KR10-2012-0069220 2012-06-27
KR1020120069220A KR101278572B1 (en) 2011-10-18 2012-06-27 Pharmaceutical combinations of leukotriene antagonist and epinastine and their preparing methods

Publications (2)

Publication Number Publication Date
WO2013058527A2 WO2013058527A2 (en) 2013-04-25
WO2013058527A3 true WO2013058527A3 (en) 2013-06-20

Family

ID=48141524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/008458 Ceased WO2013058527A2 (en) 2011-10-18 2012-10-17 Combined formulation of leukotriene antagonist and epinastine

Country Status (1)

Country Link
WO (1) WO2013058527A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (en) 2010-06-10 2013-02-06 주식회사 네비팜 A composition for treating or preventing osteoporosis and a method of preparing the same
CN103251563A (en) * 2013-05-22 2013-08-21 北京科源创欣科技有限公司 Stable granular medicine composition containing epinastine or hydrochloride thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100737710B1 (en) * 1997-12-23 2007-07-11 쉐링 코포레이션 Compositions for the treatment of respiratory and skin diseases comprising at least one leukotriene antagonist and descaboethoxyloratidine
KR20080016621A (en) * 2005-06-09 2008-02-21 바이올리폭스 에이비 Compositions and methods for treating inflammatory diseases
KR20090103810A (en) * 2008-03-28 2009-10-01 코와 가부시키가이샤 Tablet
US20110189274A1 (en) * 2008-10-06 2011-08-04 Swati Mukherjee Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100737710B1 (en) * 1997-12-23 2007-07-11 쉐링 코포레이션 Compositions for the treatment of respiratory and skin diseases comprising at least one leukotriene antagonist and descaboethoxyloratidine
KR20080016621A (en) * 2005-06-09 2008-02-21 바이올리폭스 에이비 Compositions and methods for treating inflammatory diseases
KR20090103810A (en) * 2008-03-28 2009-10-01 코와 가부시키가이샤 Tablet
US20110189274A1 (en) * 2008-10-06 2011-08-04 Swati Mukherjee Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALISE REICIN ET AL.: "Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma", ARCHIVES INTERNAL MEDICINE, vol. 160, 2000, pages 2481 - 2488 *

Also Published As

Publication number Publication date
WO2013058527A2 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
IL229260A0 (en) Compositions,methods & systems for respiratory delivery of two or more active agents
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2011086531A3 (en) New anti-malarial agents
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2013004995A8 (en) Pyrimidinone compounds and their use
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2011157722A3 (en) Solid ivabradine-containing composition
WO2013055689A8 (en) R(+)-n-methyl-propargyl-aminoindan
WO2013055684A8 (en) Rasagiline citramide
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
MD4563B1 (en) Co-micronisation product comprising ulipristal acetate
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IL227024A (en) Amino-substituted 3-heteroaroylamino-propionic acid derivatives, process for the preparation of such compounds, uses thereof in the preparation of pharmaceuticals and pharmaceutical compositions comprising the same
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
EP2722322B8 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
WO2013058527A3 (en) Combined formulation of leukotriene antagonist and epinastine
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12841792

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014536980

Country of ref document: JP

Kind code of ref document: A

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/08/2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12841792

Country of ref document: EP

Kind code of ref document: A2